MDGL Madrigal Pharmaceuticals

Watchlist

322.965
-6.195-1.88%

Trading Mar 11 11:34 ET

7.13BMarket Cap-14.75P/E (TTM)

Madrigal Pharmaceuticals Key Stats

Madrigal Pharmaceuticals Q4 2024 Earnings Date

Currency：USDFeb 26, 2025

	Estimate (YoY)	Actual (YoY)	Vs Estimate (% Chg)
Revenue	97.81M	103.32M	+5.51M
Beat Est.	--	--	+5.64%
EPS	-4.10	-2.71	+1.39
Beat Est.	+27.81%	+52.62%	+33.91%

Analyst Rating

Strong Buy

Mar 6, 2025

Madrigal Pharmaceuticals Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 12 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual

Estimate

Date	Period	Revenue/Estimate	Earnings Call
--	2025/Q2	-- / 139.244M	--
--	2025/Q1	-- / 114.124M	--
Feb 26, 2025	2024/Q4	103.320M / 97.808M	--
Oct 31, 2024	2024/Q3	62.175M / 34.414M	--
Aug 7, 2024	2024/Q2	14.638M / 4.383M	--

DatePeriodRevenue/EstimateEarnings Call

--2025/Q2-- / 139.244M--

--2025/Q1-- / 114.124M--

Feb 26, 20252024/Q4103.320M / 97.808M--

Oct 31, 20242024/Q362.175M / 34.414M--

Aug 7, 20242024/Q214.638M / 4.383M--

Unlock Free Earnings Estimates

Open Account

Madrigal Pharmaceuticals Earnings Reports

Madrigal Pharmaceuticals | 10-K: FY2024 Annual Report

Feb 26 09:12 ET

Madrigal Pharmaceuticals | 8-K: Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra (resmetirom) in Patients with Compensated MASH Cirrhosis

Feb 26 07:07 ET

Madrigal Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

Oct 31, 2024 09:06 ET

Madrigal Pharmaceuticals | 8-K: Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates

Oct 31, 2024 07:10 ET

Trending Stocks